CSF2 and melanoma: In patients with stage IIIB–IVM1a melanoma, median OS was longer in the talimogene laherparepvec arm (41 months; 95% CI, 31 months, not evaluable), compared with the GM-CSF arm (21.5 months; 95% CI, 17, 30 months).